Emergent BioSolutions (EBS) Tops Q4 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Emergent BioSolutions (EBS) PT Raised to $71 at Chardan Capital Markets
February 22, 2019 6:47 AM ESTChardan Capital Markets analyst Keay Nakae raised the price target on Emergent BioSolutions (NYSE: EBS) to $71.00 (from $66.00) while maintaining a Buy rating.
The analyst commented, "We believe that the two recently announced acquisitions check a number of boxes that support he... More
